DUBLIN, Dec. 11, 2014 /PRNewswire/ --Research and Markets
(http://www.researchandmarkets.com/research/zxp6kr/global_antisense) has announced the addition of the "Global Antisense and RNAi Therapeutics Market 2015-2019" report to their offering.
http://photos.prnewswire.com/prnh/20130307/600769
Antisense and RNAi therapeutics are new innovative therapeutics options that are used in the treatment of serious chronic and rare diseases. RNAi is a RNA-based gene silencing process in which RNA molecules inhibit gene expression by destructing definite mRNA molecules. Antisense technology involves the synthesis of a strand of nucleic acid that would bind to an mRNA or to a splicing site on pre-mRNA and inactivates it effectively.
RNAi and antisense are two predominant technologies used by pharmaceutical companies, research institutes, and others for various applications such as research, diagnostics, and therapeutics. RNAi therapeutics have a large scope in the treatment of diseases such as cancer and neurodegenerative disorders. There are two types of RNA molecules used in the RNAi technology: miRNA and siRNA.
The analysts forecast the Global Antisense and RNAi Therapeutics market to grow at a CAGR of 26.79 percent over the period 2014-2019.
This report covers the present scenario and the growth prospects of the Global Antisense and RNAi Therapeutics market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of antisense and RNAi therapeutics used for the treatment of various serious chronic diseases including:
- Infectious diseases
- Cardiovascular diseases
- Kidney diseases
- Cancer
- Metabolic disorders
- Others
One of the main trends upcoming in this market is the increased strategic collaborations and licensing activities. Many big pharmaceutical and biotechnology companies are collaborating with other companies to develop and commercialize antisense and RNAi drugs in the market.
According to the report, one of the major drivers in this market is the advances in technology. Demand for gene silencing by antisense and RNAi is gaining popularity because of its high efficiency. Advances in technology in antisense and RNAi technology help to design and develop antisense and RNAi therapeutics that can suppress the expression of the targeted genes with high specificity.
Further, the report states that one of the major challenges in this market is the toxicity of antisense and RNAi-based drugs. Therapeutic antisense oligonucleotides and RNAi drugs have adverse side effects on the body especially on the liver.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Market Landscape
07. Market Segmentation by Technology
08. Market Segmentation by Therapeutics Area
09. Geographical Segmentation
10. Buying Criteria
11. Pipeline Snapshot
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
19. Key Vendor Analysis
20. Other Reports in this Series
Companies Mentioned:
- Alnylam Pharmaceuticals
- Isis Pharmaceuticals
- Sanofi
- Tekmira Pharmaceuticals
- Acuitas Therapeutics
- Allergan
- Antisense Therapeutics
- Ascletis
- AstraZeneca
- Atlantic Pharmaceuticals
- Benitec Biopharma
- Biogen Idec
- Bristol-Myers Squibb
- Dainippon SumitomoPharma
- Dicerna Pharmaceuticals
- Enzon Pharmaceuticals
- F. Hoffmann-La Roche
- Glaxosmithkline
- Gradalis
- iCo Therapeutics
- Kyowa Hakko Kirin
- Marina Biotech
- Novartis
- OncoGenex Pharmaceuticals
- OPKO Health
- Pfizer
- Quark Pharmaceuticals
- RegulusTherapeutics
- Silence Therapeutics
- Spectrum Pharmaceuticals
- Sylentis
- Takeda Pharmaceutical
- Teva Pharmaceutical
- The Medicines Company
- TransDerm
For more information visit http://www.researchandmarkets.com/research/zxp6kr/global_antisense
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
